Cargando…
Transcription factorIRX5 promotes hepatocellular carcinoma proliferation and inhibits apoptosis by regulating the p53 signalling pathway
Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most frequent cause of cancer‐related death. The IRX5 transcription factor plays a different role in multiple cancers and contributes to the development of many tumours. However, little is known about the molecula...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384050/ https://www.ncbi.nlm.nih.gov/pubmed/32153043 http://dx.doi.org/10.1002/cbf.3517 |
_version_ | 1783563545421545472 |
---|---|
author | Zhu, Liying Dai, Longguang Yang, Nenghong Liu, Mi Ma, Shuang Li, Chengcheng Shen, Jie Lin, Tao Wang, Dan Pan, Wei Li, Xing |
author_facet | Zhu, Liying Dai, Longguang Yang, Nenghong Liu, Mi Ma, Shuang Li, Chengcheng Shen, Jie Lin, Tao Wang, Dan Pan, Wei Li, Xing |
author_sort | Zhu, Liying |
collection | PubMed |
description | Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most frequent cause of cancer‐related death. The IRX5 transcription factor plays a different role in multiple cancers and contributes to the development of many tumours. However, little is known about the molecular mechanisms of IRX5 in HCC. In this study, we found that IRX5 was abnormally upregulated in HCC tissues compared with adjacent normal tissues. IRX5 promoted HCC cell proliferation and upregulated the expression of cyclin D1 and knockdown of IRX5 suppressed tumorigenicity in vivo. Furthermore, knockdown of IRX5 increased p53 and Bax expression and decreased Bcl‐2 expression. Thus, IRX5 suppressed apoptosis in HCC cells by inhibiting the p53 signalling pathway, indicating its role as a treatment target for HCC. SIGNIFICANCE OF THE STUDY: Our study demonstrated that IRX5 was abnormally upregulated in HCC tissues compared with adjacent normal tissues. IRX5 promoted HCC cell proliferation and upregulated the expression of cyclin D1, and knockdown of IRX5 suppressed tumorigenicity in vivo. Furthermore, knockdown of IRX5 increased p53 and Bax expression and decreased Bcl‐2 expression. IRX5 suppressed apoptosis in HCC cells by inhibiting the p53 signalling pathway, indicating its role as a treatment target for HCC. |
format | Online Article Text |
id | pubmed-7384050 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-73840502020-07-28 Transcription factorIRX5 promotes hepatocellular carcinoma proliferation and inhibits apoptosis by regulating the p53 signalling pathway Zhu, Liying Dai, Longguang Yang, Nenghong Liu, Mi Ma, Shuang Li, Chengcheng Shen, Jie Lin, Tao Wang, Dan Pan, Wei Li, Xing Cell Biochem Funct Research Articles Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the third most frequent cause of cancer‐related death. The IRX5 transcription factor plays a different role in multiple cancers and contributes to the development of many tumours. However, little is known about the molecular mechanisms of IRX5 in HCC. In this study, we found that IRX5 was abnormally upregulated in HCC tissues compared with adjacent normal tissues. IRX5 promoted HCC cell proliferation and upregulated the expression of cyclin D1 and knockdown of IRX5 suppressed tumorigenicity in vivo. Furthermore, knockdown of IRX5 increased p53 and Bax expression and decreased Bcl‐2 expression. Thus, IRX5 suppressed apoptosis in HCC cells by inhibiting the p53 signalling pathway, indicating its role as a treatment target for HCC. SIGNIFICANCE OF THE STUDY: Our study demonstrated that IRX5 was abnormally upregulated in HCC tissues compared with adjacent normal tissues. IRX5 promoted HCC cell proliferation and upregulated the expression of cyclin D1, and knockdown of IRX5 suppressed tumorigenicity in vivo. Furthermore, knockdown of IRX5 increased p53 and Bax expression and decreased Bcl‐2 expression. IRX5 suppressed apoptosis in HCC cells by inhibiting the p53 signalling pathway, indicating its role as a treatment target for HCC. John Wiley and Sons Inc. 2020-03-09 2020-07 /pmc/articles/PMC7384050/ /pubmed/32153043 http://dx.doi.org/10.1002/cbf.3517 Text en © 2020 The Authors. Cell Biochemistry and Function published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Zhu, Liying Dai, Longguang Yang, Nenghong Liu, Mi Ma, Shuang Li, Chengcheng Shen, Jie Lin, Tao Wang, Dan Pan, Wei Li, Xing Transcription factorIRX5 promotes hepatocellular carcinoma proliferation and inhibits apoptosis by regulating the p53 signalling pathway |
title | Transcription factorIRX5 promotes hepatocellular carcinoma proliferation and inhibits apoptosis by regulating the p53 signalling pathway |
title_full | Transcription factorIRX5 promotes hepatocellular carcinoma proliferation and inhibits apoptosis by regulating the p53 signalling pathway |
title_fullStr | Transcription factorIRX5 promotes hepatocellular carcinoma proliferation and inhibits apoptosis by regulating the p53 signalling pathway |
title_full_unstemmed | Transcription factorIRX5 promotes hepatocellular carcinoma proliferation and inhibits apoptosis by regulating the p53 signalling pathway |
title_short | Transcription factorIRX5 promotes hepatocellular carcinoma proliferation and inhibits apoptosis by regulating the p53 signalling pathway |
title_sort | transcription factorirx5 promotes hepatocellular carcinoma proliferation and inhibits apoptosis by regulating the p53 signalling pathway |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384050/ https://www.ncbi.nlm.nih.gov/pubmed/32153043 http://dx.doi.org/10.1002/cbf.3517 |
work_keys_str_mv | AT zhuliying transcriptionfactorirx5promoteshepatocellularcarcinomaproliferationandinhibitsapoptosisbyregulatingthep53signallingpathway AT dailongguang transcriptionfactorirx5promoteshepatocellularcarcinomaproliferationandinhibitsapoptosisbyregulatingthep53signallingpathway AT yangnenghong transcriptionfactorirx5promoteshepatocellularcarcinomaproliferationandinhibitsapoptosisbyregulatingthep53signallingpathway AT liumi transcriptionfactorirx5promoteshepatocellularcarcinomaproliferationandinhibitsapoptosisbyregulatingthep53signallingpathway AT mashuang transcriptionfactorirx5promoteshepatocellularcarcinomaproliferationandinhibitsapoptosisbyregulatingthep53signallingpathway AT lichengcheng transcriptionfactorirx5promoteshepatocellularcarcinomaproliferationandinhibitsapoptosisbyregulatingthep53signallingpathway AT shenjie transcriptionfactorirx5promoteshepatocellularcarcinomaproliferationandinhibitsapoptosisbyregulatingthep53signallingpathway AT lintao transcriptionfactorirx5promoteshepatocellularcarcinomaproliferationandinhibitsapoptosisbyregulatingthep53signallingpathway AT wangdan transcriptionfactorirx5promoteshepatocellularcarcinomaproliferationandinhibitsapoptosisbyregulatingthep53signallingpathway AT panwei transcriptionfactorirx5promoteshepatocellularcarcinomaproliferationandinhibitsapoptosisbyregulatingthep53signallingpathway AT lixing transcriptionfactorirx5promoteshepatocellularcarcinomaproliferationandinhibitsapoptosisbyregulatingthep53signallingpathway |